Inhibitor Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Black Robe Capital LLC and 1 other reported changes in beneficial ownership of Inhibitor Therapeutics, Inc. common stock on July 1, 2026.
OQB
Ronald E Osman and 1 other reported changes in beneficial ownership of Inhibitor Therapeutics, Inc. common stock on May 4, 2026.
OQB
Michelle Yanez, a Director of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Samuel P Sears Jr, a Director of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Francis E Odonnell Jr, Chief Executive Officer, a Director and 10% owner of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
OQB
Michael Jerman, a Director at Inhibitor Therapeutics, Inc., was issued 50,000 shares of common stock as compensation on May 4, 2026.
OQB
Niraj Vasisht, a Director at Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock as compensation.
OQB
Director Niraj Vasisht reports acquisition of 50,000 shares of restricted common stock as compensation and disposal of 150,000 shares.
OQB
Form 4: Inhibitor Therapeutics Director Michelle Yanez Reports Acquisition of 50,000 Shares of Common Stock
Michelle Yanez, a director of Inhibitor Therapeutics, Inc., reported acquiring 50,000 shares of common stock on April 1, 2025.
OQB
Director Samuel P. Sears Jr. acquired 50,000 shares of Inhibitor Therapeutics common stock as compensation.
OQB
Form 4: Inhibitor Therapeutics Director Ronald Osman Receives 50,000 Shares of Restricted Common Stock
Director Ronald Osman acquired 50,000 shares of restricted common stock in Inhibitor Therapeutics as compensation.
OQB
Director Michael Jerman reports acquiring 50,000 shares of Inhibitor Therapeutics common stock as compensation and disposing of 80,411 shares.
OQB
Director Michelle Yanez acquired 50,000 shares of Inhibitor Therapeutics common stock on April 1, 2024, as compensation under the company's 2014 Equity Incentive Plan.
OQB
James McNulty, CFO of Inhibitor Therapeutics, acquired 100,000 stock options on March 16, 2024, which vested immediately.
OQB
Director Samuel P. Sears Jr. of Inhibitor Therapeutics, Inc. reports acquiring 50,000 shares of common stock on April 1, 2024, as compensation.
OQB
Form 4: Inhibitor Therapeutics Director Ronald Osman Acquires 50,000 Shares of Restricted Common Stock
Director Ronald Osman acquired 50,000 shares of Inhibitor Therapeutics' restricted common stock as compensation on April 1, 2024.
OQB
Director Michael Jerman acquired 50,000 shares of Inhibitor Therapeutics common stock on April 1, 2024, as compensation under the company's 2014 Equity Incentive Plan.